-
A Predictive Model for BCG-Unresponsiveness and Progression Based on Five Clinical Factors: A Study of 2,211 Patients
During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC)…
-
Optimizing mRCC Therapy: Morning Infusion of Immune Checkpoint Inhibitors Associated with a 38% Reduction in Mortality Risk
At a recent international uro-oncology symposium, Dr. Takemura K. from the Department of Genitourinary Oncology at the Japanese Foundation for Cancer Research (JFCR), Ariake Hospital, presented findings from a multicenter retrospective study investigating the correlation between the time-of-day administration (ToDA) of first-line immune checkpoint inhibitors (ICIs) and overall survival (OS) in patients with metastatic renal…
-
Toward a “Chemo-Free” Future: Exploring Disitamab Vedotin plus Tislelizumab in the Adjuvant Setting for UTUC
During the recent academic conference, Professor Liangyou Gu from the People’s Liberation Army General Hospital (PLAGH) presented the latest findings from a prospective, controlled, phase II study. The study evaluated the efficacy and safety of Disitamab Vedotin (DV/RC48), a HER2-targeted antibody-drug conjugate (ADC), combined with Tislelizumab (a PD-1 inhibitor) as adjuvant therapy for patients with…
-
1-Year DFS Reaches 93%! RC48-ADC Plus Radiotherapy Breaks the Adjuvant Treatment Dilemma for Cisplatin-Ineligible UTUC
During a recent academic session, Dr. Tao Zihao from Peking University First Hospital presented the preliminary results of a Phase II study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in combination with radiotherapy for the adjuvant treatment of Upper Tract Urothelial Carcinoma (UTUC). This study provides a potential new therapeutic strategy for high-risk…
-
71.9% CR Rate at 3 Months: RC48 Combined with PD-1 Inhibitors Emerges as a Promising Bladder-Sparing Strategy for HR-NMIBC
At a recent academic symposium, Dr. Xuanjun Guo (Peking University First Hospital) presented data from a multicenter real-world study evaluating the efficacy and safety of Disitamab Vedotin (RC48), a humanized anti-HER2 antibody-drug conjugate (ADC), administered as monotherapy or in combination with PD-1 inhibitors for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This study provides critical real-world evidence…
-
EAU26 Afternoon Tea Dialogue | Prof. Jianming Guo’s Team: Disease-Specific AI Large Model Enables Precise Preoperative Assessment of Renal Cancer
The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most important global academic platforms in urology.
-
Voice of China at ASCO-GU | Prof. Haige Chen and Prof. Ruiyun Zhang: Renji Hospital’s Urothelial Carcinoma Team Showcases Multiple Studies on the International Stage, Advancing Bladder-Preserving Therapy and Liquid Biopsy
The 2026 ASCO Genitourinary Cancers Symposium (ASCO-GU) recently concluded successfully in San Francisco, USA. As one of the most influential global academic conferences in the field of genitourinary oncology, the meeting brings together the latest research advances and evolving clinical perspectives from around the world.
-
EAU26 Afternoon Tea Dialogue | Prof. Jianming Guo’s Team: Hormone Therapy Combined with Cytoreductive Surgery Offers a New Strategy for Oligometastatic Prostate Cancer
The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most influential academic platforms in global urology.
Connecting Medical Expertise through Media